Biopharmaceutical Newsweek 35 2014
Biopharmaceutical NewsWeek # 6
Acquisitions /Mergers/Joint-ventures
August 25, 2014
Roche buys InterMune for $8.3 billion
Roche is to acquire InterMune Inc, based in Brisbane, California, for $8.3 billion in cash to gain access to that company portfolio that includes pirfenidone, for the treatment of idiopathic pulmonary fibrosis. Pirfenidone is an already marketed product in the European Union and in Canada, The acquisition is the largest by Roche since 2009, when it bought out the remaining stake it did not already own in Genentech for $47 billion. The deal is a further step by Roche to diversify away from its reliance on cancer drugs, where it is the world leader. Roche already markets Pulmozyme for cystic fibrosis and Xolair for severe asthma in the United States. The FDA is to give its verdict on the approval of pirfernidone on November 23.
Medtronic Inc has paid €150 million in cash to acquire Sapiens Steering Brain Stimulation BV, a Dutch company developing deep brain stimulation technologies for the treatment of the movement symptoms of Parkinson’s disease.
August 26, 2014
Cilag GmbH International, an indirect affiliate of Johnson & Johnson Inc, has acquired Covagen AG from Covagen’s venture capital and other private investors for an undisclosed amount.
Business
August 21, 2014
Illumina, based in San Diego, California, has inked deals with Astra Zeneca, Janssen and Sanofi with the goal of developing a universal gene-sequencing companion diagnostic test system focused on cancer.
Cancer immunotherapy combination therapies
For many years it has been known that combination therapy of cytotoxic agents is more efficient than monotherapy. Several companies are now testing this concept with immunotherapy agents and already established drugs.
August 25, 2014
Merck & Co has signed an immunotherapy pact with Advaxis for prostate cancer involving its high-profile PD-1 checkpoint inhibitor pembrolizumab. The collaboration will evaluate Advaxis' Lm (Listeria monocytogenes)-LLO cancer immunotherapy ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase I/II study of patients with previously treated metastatic, castration-resistant prostate cancer. No financial details have been disclosed.
August 26, 2014
Pfizer and Merck said they will explore, in a Phase 1b study, the safety and tolerability of a combination therapy in patients with anaplastic lymphoma kinase-positive (ALK-positive) advanced or metastatic non-small cell lung cancer. The combination consists of Pfizer's Xalkori (crizotinib) and Merck's investigational anti-PD-1 Ab pembrolizumab. Crizotinib inhibits an abnormally activated enzyme in patients with ALK-positive.
Approval of drugs
August 26,2014
The Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta/Revolade (eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy. SAA is a disorder where the bone marrow fails to make enough red blood cells, white blood cells, and platelets.
Drugs at clinical stage
August 27, 2014
Amgen heart failure drug gets FDA priority review
The US Food and Drug Administration has granted Amgen a priority review for ivabradine, licensed from Servier, for the treatment of chronic heart failure. The latest designation comes some four months after the FDA granted fast track designation for ivabradine, which is already approved in Europe under the brand name Procoralan for stable angina and chronic heart failure. Amgen got US rights to sell the pill through a cross-licensing pact signed with Servier a year ago.
August 29, 2014
Amgen files cholesterol drug evolocumab in USA
Amgen has filed its cholesterol drug evolocumab in the USA, the first PCSK9 inhibitor to be submitted to regulators. The filing with the US Food and Drug Administration contains data from 6,800 patients, including more than 4,500 patients with high cholesterol in ten Phase III trials. Evolocumab has shown high levels of efficacy in patients with elevated cholesterol on statins with or without other lipid-lowerers, those who cannot tolerate statins and those patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder. Evolocumab belongs to the closely-watched PCSK9 class, a protein that reduces the liver's ability to remove bad cholesterol, from the blood. It is in a race with Sanofi/Regeneron’s alirocumab to see which will first get to market.
Miscellaneaous
August 26, 2014
First Briton being treated for Ebola in London
Doctors at a London hospital have started treating the first confirmed case of a Briton with Ebola during the present outbreak. William Pooley, who contracted Ebola while working as a volunteer nurse in Sierra Leone, was flown to RAF Northolt at the weekend and taken under police escort to the Royal Free Hospital. He is being treated at the hospital’s high level isolation unit, the only one of its kind in Europe. Meantime the World Health Organisation (WHO) has commented on the “unprecedented number of medical staff infected with Ebola”. More than 240 healthcare workers have developed the disease in Guinea, Liberia, Nigeria, and Sierra Leone, and more than 120 have died. The agency notes that the loss of so many doctors and nurses “has made it difficult for WHO to secure support from sufficient numbers of foreign medical staff”. The World Health Organization says that the Ebola cases are accelerating. Forty percent of the infections have happened in the last 21 days. More than 20,000 people may be infected before the outbreak is contained.
Eight companies are working on Ebola vaccines/therapies:
- Tekmira Pharmaceuticals: TKM-Ebola in Phase 1
- Sarepta Therapeutics: AVI-7537 in Preclinicals
- NewLink Genetics: Ebola Vaccine in Preclinicals
- BioCryst Pharmaceuticals : BCX4430 in Preclinicals
- Nanoviricides: NV-INF-1 in Preclinicals
- FujiFilm: Favipiravir in Preclinicals
- Mapp Pharmaceuticals: ZMapp in Preclinicals.
- GlaxoSmithKline: Ebola Vaccine in Preclinicals
- Inovio Pharmaceuticals: SynCon DNA Vaccine in Preclinicals
Author : Jean-Claude MULLER, Special Advisor,Innovation & International Relationship (I&IR)
Discover our services in Marketing & Business Development:
See All News
See other Biopharmaceutical News
see other Pharma & Biotech events in 2014
Last News
- Note de réflexion de fin d’année
- EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease
- Le déclassement de la France
Events
News archives
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012